Pfizer PFE1.16%increase; green up pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 0.58%increase; green up pointing triangle for 2.50 billion pounds ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million ...

Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. After charting similar ...

Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne toothpaste.

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each.

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...